Table 4.
Factors |
Univariable Analysis |
Multivariable Analysis (adjusted to PLEX) |
||||
---|---|---|---|---|---|---|
OR | 95% CI | P-value | OR | 95% CI | P-value | |
Age ˂ 60 yr | 0.933 | 0.336–2.591 | 0.895 | |||
Male | 1.034 | 0.375–2.853 | 0.948 | |||
GPA | 2.700 | 1.004–7.260 | 0.049a | |||
PR3 | 2.456 | 0.917–6.579 | 0.074 | |||
Alveolar hemorrhage | 1.004 | 0.351–2.868 | 0.994 | |||
Hb at diagnosis ---- | 1.432 | 1.014–2.024 | 0.042a | |||
Erythrocyte sedimentation rate at diagnosis | 1.013 | 0.995–1.031 | 0.171 | |||
SCr at diagnosis | 0.800 | 0.669–0.956 | 0.014a | |||
eGFR at diagnosis | 1.069 | 1.001–1.141 | 0.046a | |||
MCCS | ||||||
Minimal | 8.039 | 1.965–32.884 | 0.004a | 6.138 | 1.389–27.118 | 0.017a |
Mild | 1.137 | 0.419–3.089 | 0.801 | |||
Moderate | 0.500 | 0.167–1.496 | 0.215 | |||
Severe | 0.131 | 0.016–1.087 | 0.060 | |||
MCCS score | 0.728 | 0.593–0.893 | 0.002a | |||
Berden | ||||||
Focal | 6.875 | 1.906–24.798 | 0.003a | 5.017 | 1.287–19.567 | 0.020a |
Crescentic | 1.329 | 0.494–3.573 | 0.573 | |||
Mixed | 0.276 | 0.081–0.938 | 0.039a | |||
Sclerotic | 0.203 | 0.024–1.753 | 0.147 | |||
Intervention | ||||||
Remission-induction treatment | ||||||
Rituximab (vs. CYC) ---- | 1.335 | 0.497–3.587 | 0.567 | |||
Remission-induction adjuvant therapies | ||||||
Plasma exchange | 1.745 | 0.661–4.606 | 0.261 | 1.650 | 0.548–4.965 | 0.373 |
i.v. methylprednisolone | 1.603 | 0.288–8.905 | 0.590 |
CI, confidence interval; CYC, Cyclophosphamide; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; GPA, granulomatosis with polyangiitis; MCCS, Mayo Clinic Chronicity score; OR, odds ratio; PLEX, plasma exchange; PR3, proteinase 3; Scr, serum creatinine.
P ≤ 0.05, indicate statistical significance.